Akshaya Bio Inc Information

Akshaya Bio, Inc., a Canadian development stage biotechnology company ("Akshaya"), and its wholly owned subsidiary Chimigen Inc., a US-based company ("Chimigen"), develop innovative therapeutics for infectious diseases and cancer-based vaccines using its proprietary Chimigen® Platform Technology. The Chimigen® Platform's unique competitive advantage lies in its design, consisting of a chimeric protein made up of the antigen and antibody mimicking the normal and effective biological process of inducing an immune response initiated through antigen-antibody complexes. Furthermore, the proprietary design also mimics the natural process of targeting receptors on antigen presenting cells such as dendritic cells to elicit broad immune responses. Additionally, manufacture of the chimeric antigen in insect cells provides for additional immunogenicity to Chimigen® Technology-derived product candidates. Akshaya's intellectual property-protected Chimigen® Platform has been used to develop a portfolio of dendritic cell receptor-targeted chimeric molecules which have therapeutic as well as prophylactic applications (immunotherapies and vaccines) that address several major current medical needs. Akshaya's business strategy is to develop and commercialize immunotherapeutic products in infectious diseases and cancer, and currently focusing on Chimigen® HBV Immunotherapy Vaccine and Chimigen® SARS-CoV-2 (COVID-19) for prophylactic use to prevent infection by SARS-CoV-2. Akshaya is currently in discussions with NIH-NIAID for support with HBV clinical studies and other US and Canadian Government Agencies for support with COVID-19 vaccine development. Akshaya is also seeking to attract venture financing to advance development of the product.